NIKA Pharmaceuticals Reports Zero Revenue, Narrows Q3 Loss Amidst Going Concern Doubts

TL;DR

**NIKA is a pre-revenue pharmaceutical company with a massive accumulated deficit, making it a high-risk gamble on future potential that currently lacks any tangible product or sales.**

AI Summary

NIKA PHARMACEUTICALS, INC. (NIKA) reported no revenue for the three and nine months ended September 30, 2025, continuing its trend of zero revenue from the prior year. The company posted a net loss of $7,999 for the three months ended September 30, 2025, a slight improvement from a net loss of $8,367 in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $39,309, significantly lower than the $83,340 net loss for the nine months ended September 30, 2024. Total operating expenses decreased to $39,309 for the nine-month period in 2025 from $83,340 in 2024, primarily due to reduced professional fees and general and administrative expenses. Cash increased to $6,287 as of September 30, 2025, from $2,083 at December 31, 2024, largely due to $45,000 in loans from related parties. The company has an accumulated deficit of $8,966,920 as of September 30, 2025, raising substantial doubt about its ability to continue as a going concern without additional capital.

Why It Matters

NIKA's continued lack of revenue and significant accumulated deficit of $8,966,920 signals extreme caution for investors, highlighting a business model that has yet to generate any income. The reliance on related-party loans, totaling $45,000 in the current period, to fund operations is a red flag, indicating a lack of independent financial viability. For employees, the going concern risk suggests job insecurity, while customers have no products or services to evaluate. In a competitive pharmaceutical market, NIKA's inability to launch products or generate sales puts it far behind established players, making it a highly speculative venture.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $8,966,920 as of September 30, 2025, and has generated no revenue to date, which are explicit factors raising substantial doubt about its ability to continue as a going concern. Its operations are currently funded by loans from related parties, including $45,000 from Nika Europe, Ltd. and $205,164 from CEO Dimitar Slavchev Savov, indicating a lack of sustainable independent funding.

Analyst Insight

Investors should avoid NIKA PHARMACEUTICALS, INC. given its pre-revenue status, substantial accumulated deficit of $8,966,920, and explicit going concern warning. The company's reliance on related-party financing suggests a high-risk profile with no clear path to profitability or independent operations.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$23,625

total Debt

$284,164

net Income

$(39,309)

eps

$0.00

gross Margin

N/A

cash Position

$6,287

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the three and nine months ended September 30, 2025 and 2024.)
• $(39,309) — Net Loss (9 months) (Net loss for the nine months ended September 30, 2025, an improvement from $(83,340) in 2024.)
• $(8,966,920) — Accumulated Deficit (Accumulated deficit as of September 30, 2025, indicating significant historical losses.)
• $6,287 — Cash (Cash balance as of September 30, 2025, up from $2,083 at December 31, 2024.)
• $45,000 — Loans from Nika Europe, Ltd. (Amount advanced to the company by Nika Europe, Ltd. during the nine months ended September 30, 2025.)
• $205,164 — Due to CEO Dimitar Slavchev Savov (Total amount due to the CEO as of September 30, 2025, for advanced operating expenses.)
• 1,039,836,001 — Common Shares Outstanding (Number of common shares outstanding as of November 7, 2025.)
• $(7,999) — Net Loss (3 months) (Net loss for the three months ended September 30, 2025, an improvement from $(8,367) in 2024.)
• $39,309 — Total Operating Expenses (9 months) (Total operating expenses for the nine months ended September 30, 2025, down from $83,340 in 2024.)
• $284,164 — Total Current Liabilities (Total current liabilities as of September 30, 2025, primarily due to related parties.)

Key Players & Entities

• NIKA PHARMACEUTICALS, INC. (company) — registrant
• Dimitar Slavchev Savov (person) — CEO, CFO, President, Director, and General Manager of Nika Europe, Ltd.
• Nika Europe, Ltd. (company) — related party that advanced $45,000 to NIKA
• Nika BioTechnology, Inc. (company) — target company in a common control merger
• Clifford Redekop (person) — Director and Secretary of NIKA
• Phil E. Ray (person) — former Director, President, and CEO of NIKA
• A. Terry Ray (person) — former Director and Secretary of NIKA
• Nika Pharmaceuticals, Ltd. (company) — related party that advanced $34,000 to NIKA
• EDGARhub LLC (company) — filer of the 10-Q form
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has an accumulated deficit of $8,966,920 as of September 30, 2025, and reported no revenue. This raises substantial doubt about its ability to continue as a going concern without additional capital, which may be raised through equity sales, debt offerings, or borrowings.
• Dependence on Related Party Financing [medium — financial]: The company's cash position increased to $6,287 as of September 30, 2025, primarily due to $45,000 in loans from Nika Europe, Ltd. and $205,164 due to CEO Dimitar Slavchev Savov for advanced operating expenses. This reliance on related parties for funding presents a concentration risk.
• Lack of Revenue Generation [high — operational]: NIKA PHARMACEUTICALS, INC. reported zero revenue for the three and nine months ended September 30, 2025, continuing a trend from the prior year. This indicates a significant challenge in commercializing its products or services.
• Significant Accumulated Deficit [high — financial]: The company has accumulated a deficit of $8,966,920 as of September 30, 2025. This substantial deficit reflects persistent historical losses and a lack of profitability.
• Exclusive Rights Agreement Dependence [medium — operational]: The company has an exclusive rights agreement for Thymus Nuclear Glycoprotein (TNG) with VITAL FE Joint Stock Company, which holds the technology and Phase III clinical trial data. The company's future success may be heavily reliant on the successful development and commercialization of TNG.

Industry Context

NIKA PHARMACEUTICALS operates in the highly competitive and capital-intensive pharmaceutical industry. Success typically hinges on the discovery, development, and successful commercialization of novel therapeutics, often requiring extensive R&D and clinical trials. The industry faces stringent regulatory hurdles and patent cliffs, demanding continuous innovation and strategic partnerships.

Regulatory Implications

As a pharmaceutical company, NIKA is subject to rigorous oversight by regulatory bodies like the FDA. Any product development or commercialization efforts would require extensive clinical trials and regulatory approvals, posing significant time and financial risks. The company's current lack of revenue and substantial deficit may also attract scrutiny regarding its operational viability.

What Investors Should Do

1. Monitor future financing activities
2. Evaluate the progress of TNG development
3. Assess the sustainability of operating expense reductions

Key Dates

• 2025-09-30: Quarter End — Reporting period for the 10-Q, showing $0 revenue, a net loss of $7,999 for the quarter, and cash of $6,287.
• 2024-12-31: Year End — Prior audited period, showing cash of $2,083 and an accumulated deficit of $8,927,612.
• 2022-04-07: Exclusive Rights Agreement Signed — Agreement with VITAL for Thymus Nuclear Glycoprotein (TNG) production and distribution, involving a non-cash expense of $2,400,000 and issuance of preferred stock.

Glossary

Accumulated deficit

The total net losses of a company since its inception, minus any net gains. It represents a negative balance in retained earnings. (Indicates the company's historical unprofitability, with a significant deficit of $8,966,920 as of September 30, 2025.)

Going concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Management's ability to continue as a going concern is in doubt due to NIKA's lack of revenue and substantial deficit.)

Related parties

Entities or individuals that have the ability to control or significantly influence the financial or operating decisions of another entity. (NIKA relies heavily on financing from related parties like Nika Europe, Ltd. and its CEO, Dimitar Slavchev Savov.)

Exclusive Rights Agreement

A contract granting one party the sole right to produce or distribute a product or technology within a specified territory or for a specified period. (NIKA has an exclusive agreement for Thymus Nuclear Glycoprotein (TNG), which is crucial for its potential future operations.)

Year-Over-Year Comparison

Compared to the prior year, NIKA PHARMACEUTICALS, INC. has seen a significant reduction in operating expenses for the nine months ended September 30, 2025, decreasing from $83,340 to $39,309, primarily due to lower professional fees and general and administrative costs. This has led to a reduced net loss of $39,309 for the period, an improvement from $83,340 in the prior year. The company's cash position has also improved, rising to $6,287 from $2,083, largely due to new loans from related parties. However, the company continues to generate no revenue, and the accumulated deficit remains substantial, indicating ongoing financial challenges.

Key Financial Figures

• $0.0001 — The number of shares of Common Stock, $0.0001 par value of the registrant outstanding
• $0 — equivalent common shares were valued at $0.0003, the last sale price for common sh
• $2,400,000 — volume), for total non-cash expense of $2,400,000. On April 7, 2022, the Company signed

Filing Documents

• form-10q.htm (10-Q) — 356KB
• exhibit31-1.htm (EX-31.1) — 9KB
• exhibit32-1.htm (EX-32.1) — 3KB
• 0001826466-25-000096.txt ( ) — 2035KB
• nika-20250930.xsd (EX-101.SCH) — 17KB
• nika-20250930_cal.xml (EX-101.CAL) — 22KB
• nika-20250930_def.xml (EX-101.DEF) — 71KB
• nika-20250930_lab.xml (EX-101.LAB) — 148KB
• nika-20250930_pre.xml (EX-101.PRE) — 133KB
• form-10q_htm.xml (XML) — 201KB

Financial Statements

Financial Statements. 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 (Unaudited) 1 Condensed Consolidated Statements of Operations for the three and nine months Ended September 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Stockholders Deficit for the three and nine months Ended September 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the nine months Ended September 30, 2025 and 2024 (Unaudited) 4 Notes to UnauditedCondensed Consolidated

Financial Statements

Financial Statements 5 Item 2.

Managements Discussion and Analysis of Financial Condition

Managements Discussion and Analysis of Financial Condition and Results of Operations 11 Item 3.

Quantitative and Qualitative Disclosures About Market Risks

Quantitative and Qualitative Disclosures About Market Risks. 13 Item 4.

Controls and Procedures

Controls and Procedures 13 PART II. Item 1. Legal Proceedings. 14 Item 1A. Risk Factors. 14 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 14 Item 3. Defaults Upon Senior Securities. 14 Item 4. Mine Safety Disclosures. 14 Item 5. Other Information. 14 Item 6. Exhibits. 14 EXHIBIT INDEX 15

Consolidated Financial Statements

Item 1. Consolidated Financial Statements NIKA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ______________________________________________________________________________________________ September 30, 2025 December 31, 2024 ASSETS (Unaudited) (Audited) Current Assets: Cash $ 6,287 $ 2,083 Prepaid expenses 17,338 15,851 Total current assets 23,625 17,934 Total assets: $ 23,625 $ 17,934 LIABILITIES AND STOCKHOLDERS DEFICIT Current Liabilities: Due to related parties $ 284,164 $ 239,164 Total Current Liabilities $ 284,164 $ 239,164 Total Liabilities $ 284,164 $ 239,164 Commitments and contingencies Stockholders' Deficit: Preferred Stock; par value $ 0.0001 ; 15,000,000 shares authorized; 15,000,000 and 10,000,000 shares issued and outstanding, respectively 1,500 1,500 Common Stock; par value $ 0.0001 ; 2,700,000,000 shares authorized; 1,039,836,001 and 876,090,000 shares issued and outstanding, respectively 103,964 102,168 Additional paid-in capital 8,600,917 8,602,714 Accumulated other comprehensive income Accumulated deficit ( 8,966,920 ) ( 8,927,612 ) Total Stockholders' Deficit ( 260,539 ) ( 221,230 ) Total Liabilities and Stockholders' Deficit $ 23,625 $ 17,934 The accompanying notes are an integral part of these unaudited consolidated financial statements. 1 NIKA PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED (Unaudited) ________________________________________________________________________________________________ For the Three Months Ended For the Nine Months Ended September 30, September 30, 2025 2024 2025 2024 Revenue $ $ $ $ Operating Expenses: General and administrative $ 3,901 $ 6,302 $ 20,003 $ 28,817 Professional fees 4,081 2,065 19,307 54,523 Total operating expenses 7,982 8,367 39,309 83,340 Loss from operations ( 7,999 ) ( 8,3

financial statements reflect all adjustments, consisting of only normal

financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair necessarily indicative of the results to be expected for the full year ending December 31, 2024. These unaudited consolidated financial statements should be read in conjunction with the financial statements and related notes included in the Companys Annual Report on Form 10-K for the year ended December 31, 2024. Use of Estimate s The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial reporting period. Actual results may differ from those estimates. Concentrations of Credit Risk We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. Reclassifications Certain reclassifications have been made to the prior period financial information to conform to the presentation used in the financial Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2025 and December 31, 2024, the Company had no cash equivalents. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Centennial Ventures, Inc.

financial statements have been prepared assuming that the Company will

financial statements have been prepared assuming that the Company will continue as a going concern. The Company may raise additional capital through the sale of its equity securities, through offerings of debt securities, or through borrowings from financial institutions . These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. 7 NOTE 4 RELATED PARTY TRANSACTIONS During the period September 30, 2025, Nika Europe, Ltd., advanced the Company $ 45,000 to pay for general operating expenses. Nika Europe LTD is incorporated in Bulgaria with UIC: 206925008, the ownership of the company is divided by CEO Dimitar Slavchev Savov, Nika Pharmaceuticals, Inc. and Nika Pharmaceuticals Ltd. Dimitar Savov and Nika Pharmaceuticals, Inc. are holding below 1% of the shares of the company. Dimitar Savov is the general manager of Nika Europe. As of September 30, 2025, the total amount due to Nika Europe is $ 45,000 . The advance in non-interest bearing and due on demand. During the year ended December 31, 2024 Dimitar Slavchev Savov, CEO, advanced the Company to pay for general operating expenses. As of September 30, 2025, the total amount due to Mr. Savov is $ 205,164 . The advance in non-interest bearing and due on demand. During the year ended December 31, 2024, Nika Pharmaceuticals LTD, advanced the Company $ 34,000 , to pay for general operating expenses. Nika Pharmaceuticals LTD is incorporated in Bulgaria with UIC: 175420503 and is wholly-owned and managed by CEO Dimitar Slavchev Savov. As of September 30, 2025, the total amount due to Nika Pharmaceuticals LTD is $ 34,000 . The advance in non-interest bearing and due on demand. Exclusive Rights Agreements On April 7, 2022, the Company signed with VITAL FE Joint Stock Company (VITAL) an Exclusive Rights A

View Full Filing

View this 10-Q filing on SEC EDGAR